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Abstract
PTPRJ/CD148 is a tyrosine phosphatase that has tumour suppressor-like activity. Quantitative PCR of various cells and
tissues revealed that it is preferentially expressed in macrophage-enriched tissues. Within lymphoid tissues
immunohistochemistry revealed that PTPRJ/CD148 co-localised with F4/80, indicating that macrophages most strongly
express the protein. Macrophages express the highest basal level of ptprj, and this is elevated further by treatment with LPS
and other Toll-like receptor ligands. In contrast, CSF-1 treatment reduced basal and stimulated Ptprj expression in human
and mouse cells, and interferon also repressed Ptprj expression. We identified a 1006 nucleotide long noncoding RNA
species, Ptprj-as1 that is transcribed antisense to Ptprj. Ptprj-as1 was highly expressed in macrophage-enriched tissue and
was transiently induced by Toll-like receptor ligands with a similar time course to Ptprj. Finally, putative transcription factor
binding sites in the promoter region of Ptprj were identified.
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Introduction
Macrophages are key cells that recognise, ingest and destroy
foreign microorganisms and their products as part of the innate
immune system. Macrophages have an additional role as antigen-
presenting cells, and so are central to the optimal functioning of
both the innate and acquired immune response [1]. Pathogen-
associated molecular patterns (PAMPs) such as bacterial endotoxin
(LPS) and CpG DNA and other toll-like receptor (TLR) ligands,
induce the release of proinflammatory products such as cytokines
and chemokines, thereby enhancing pathogen clearance [2].
Ligation of surface receptors commonly activates protein phos-
phorylation cascades, which are mediated by the selective
activation of protein tyrosine kinases (PTKs). Such responses are
usually transient and can be negatively regulated by protein
tyrosine phosphatases (PTPs) [3–5], and perturbation of the
balance between PTK and PTP activity may result in a failure of
inflammation to resolve or dysregulation of cell proliferation,
which can lead to life-threatening chronic inflammatory diseases
or malignancy [6–11]. An example of this is the constitutive
tyrosine phosphorylation of the PI3 kinase/Akt pathway due to the
reduction in the activity of SHP-1 in the allelic moth-eaten viable
(Mev/Mev) mouse, resulting in severe autoimmunity [12].
PTPRJ (CD148, DEP-1, PTPg, Byp or PTPb-like tyrosine
phosphatase) is a type-III receptor PTP containing a single
cytoplasmic phosphatase domain and an extracellular domain
containing eight to twelve FNIII repeats, depending on species
[13]. PTPRJ is found in a wide range of cell types [14,15] and
evidence for a tumour suppressor role has been indicated due to its
reduced expression in some malignant tumours, its regulation by
cell density, and the reversion of the transformed phenotype when
PTPRJ function is restored [16–21]. PTPRJ has several substrates,
including PDGF b-receptor [22], hepatocyte growth factor (HGF)
receptor [23], vascular endothelial growth factor (VEGF) receptor-
2 [24] and the p85 subunit of PI3-kinase [25].
Within human and mouse tissues, macrophages exhibit the
highest expression of Ptprj [26–30], and in this cell type Ptprj
expression is up-regulated by LPS and down-regulated by CSF-1
[30]. Knockout of Ptprj indicates a positive role in monocyte
activation as it dephosphorylates the negative regulatory tyrosine
in src family kinases in a manner similar to CD45 [31,32]. Little is
known about the molecular mechanism underlying the regulation
of Ptprj expression. Although there is little data on regulation of
transcription, the 59 end of the mRNA is thought to attenuate
translation [33].
Recently, we characterized differential expression of Ptprj in
normal and cancerous human breast tissue and in the developing
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mouse mammary gland [21]. Microarray analysis of the Ptprj gene
locus identified seven probes that targeted long noncoding RNA
species originating from the first intron [21,34]. Although
previously regarded as ‘‘junk’’, it is now becoming increasingly
understood that ncRNAs play a vital role in regulating and co-
ordinating the developmental complexity of eukaryotic organisms
[35]. The differential and developmental specificity of long
ncRNA (lncRNA) expression, in combination with the widespread
conservation of their promoters, splice sites and primary sequence
[36], suggests that they are generally functional [37–39]. The
molecular mechanisms of lncRNA functions are diverse and
cannot be easily generalised, and unlike protein-coding genes,
their function cannot currently be predicted from their primary
sequence [40]. Previous functional studies of lncRNAs reveal that
they can act by influencing target gene expression at specific
genomic loci, either by directly interacting with chromatin
regulatory proteins or by modulating the activity of their
interacting partners [41–43]. While lncRNAs play important roles
during normal cellular development and differentiation [44],
lncRNAs are also associated with several diseases, including heart
disease, Alzheimer’s disease, psoriasis, and cancer [45]. In addition
to our observation of multiple lncRNAs originating from the Ptprj
locus, the potential for RNA regulation of Ptprj was also recently
highlighted by a report showing that PTPRJ is negatively regulated
by the short RNA microRNA328 [46].
Here we investigate the expression of Ptprj and an antisense
lncRNA originating from the Ptprj locus in macrophages. We show
that Ptprj is highly expressed in macrophage-enriched tissues, that
it is upregulated in response to various toll-like receptor ligands
and downregulated by CSF-1. We further show that the
expression of Ptprj-as-1, an lncRNA that is transcribed antisense
to the coding sequence, is regulated by proinflammatory factors in
a manner similar to the PTPRJ gene. Finally we characterise the
promoter region of human and mouse Ptprj and identify putative
transcription factor binding sites. An understanding of the biology
of phosphatases such as Ptprj in macrophage-specific signalling
cascades may enable the identification of key endogenous
regulators of inflammation and therapeutic targets for inflamma-
tory diseases.
Materials and Methods
Ethics Statement
All animal handing and treatment protocols were approved by
the University of Queensland Animal Ethics Committee, certifi-
cate 570-08. Mice were monitored daily for any adverse reactions
and euthanized by exposure to CO2.
Animal Handling
Bone marrow-derived macrophages (BMMs) were derived from
cells obtained from the femurs of carbon dioxide euthanized
C57BL/6 mice in accordance with University of Queensland
ethics guidelines. Thioglycollate-elicited peritoneal macrophages
(TEPMs) were obtained by injecting 6–8 week-old male mice with
1 mL of 10% w/v thioglycollate broth and recovering the
peritoneal exudate by peritoneal cavity lavage with 10 mL of
phosphate-buffered saline (PBS) 5 days post injection as described
previously [47].
Cell Culture
RPMI 1640 medium (Invitrogen Life Technologies) supple-
mented with 10% FCS (JRH Biosciences), 20 U/mL penicillin
(Invitrogen Life Technologies), 20 mg/mL streptomycin (Invitro-
gen Life Technologies), and 2 mM L-glutamine (Invitrogen Life
Technologies) (complete medium) was used for culture of RAW
264.7 cells and bone marrow-derived macrophages (BMMs).
Briefly, bone marrow cells were cultured for 7 days in complete
medium in the presence of 10,000 U/mL of recombinant human
CSF-1 (Chiron Corporation, Emeryville, CA, USA) on bacterio-
logical plastic plates. RAW 264.7 [48] cells were maintained on
bacteriological plates (Sterilin, Staffordshire, UK) in complete
media containing 5% heat-inactivated fetal bovine serum for a
maximum of four weeks in culture. RAW 264.7 cells were
passaged with an 18-gauge hypodermic needle and syringe.
NIH3T3 and HEK 293 cell lines were maintained in D-MEM
(Dulbecco/Vogt Modified Eagle’s Minimal Essential Medium,
GIBCO) supplemented with 2 mM L-glutamine (Glutamax-1,
Invitrogen), 10% heat-inactivated fetal bovine serum (JRH
Biosciences, Lenexa, KS, USA), 20 U/mL penicillin and 20 mg/
mL streptomycin (Invitrogen). The cells were cultured in T75 filter
cap flasks (Nunc). All primary cells were maintained in a 37uC
incubator containing 5% CO2. Lipopolysaccharide (from Salmo-
nella Minnesota, Sigma Aldrich, St. Louis, MO, USA) was used at
a final concentration of 10 ng/mL. Recombinant human colony
stimulating factor-1 (a gift from Chiron, Emeryville, CA, USA)
was used at a final concentration of 104 U/mL. Phorbol 12-
myristate 13-acetate (PMA) (Sigma Chemical Co.) was used at a
final concentration of 1027 M. Where shown, cells were treated
with 10 mg/mL of anti-CD148 antibody or hamster isotype
control antibody (Serotec).
Quantitative Real Time PCR
RNA extraction from mammalian cells or tissues was performed
using the RNeasy mini kit (Qiagen, Valencia, CA, USA) as per the
manufacturer’s instructions. RNA was quantified by spectropho-
tometry at 260 and 280 wavelengths. RNA purity was ensured by
an A260/A280 of at least 1.8. Genomic DNA contamination was
removed from RNA preparations using DNase (Ambion, Austin,
TX, USA) and cDNA was synthesised from 2–5 mg of total RNA
using Superscript III (Invitrogen, Carlsbad, CA, USA), using oligo-
dT primers (Geneworks, Adelaide, Australia). cDNA was quan-
titated using SYBR Green (Applied Biosystems, Foster City, CA,
USA) in 20 mL reactions in a 96 well plate. Each cDNA was
quantified in experimental triplicate. No amplification controls (a
minus-reverse transcriptase control and a minus sample control)
were included in each reaction plate to ensure the absence of
contaminating genomic DNA. Data was collected and analysed
using the ABI Prism software. Gene expression was determined
relative to Hprt (hypoxanthine-guanine phosphoribosyl transferase)
mRNA using the comparative threshold method as previously
described [21]. Calculations were performed in Microsoft Excel
following equations provided by Applied Biosystems. Unless
otherwise stated, error bars in figures indicate the standard
deviation of duplicate cDNA quantitation in the same thermal
cycle run. Expression profiles were typically quantitated in at least
two separate experiments (as stated in the figure legends) using
completely independent preparations of cells and RNA extracts.
Primers (f, forward; r, reverse) used were as follows: mouse csf1r f:
CCAGAGCCCCCACAGATAA, r: AGCTTGCTGTCTC-
CACGTTTG; human csf1r f: CCTTCAGGAGCAGGCCCAAG,
r: CCTTGCTCGCAGCAGGTCAG; mouse Ptprj f: CAGTA-
CAGTGAATGGGAGCACTGAC, r: GTCCGTATTCTGC-
CACTCCAACT; human Ptprj f: AGTACACACGGCCCAG-
CAAT, r: GAGGCGTCATCAAAGTTCTGC; mouse Ptprj-as1 f:
CCATCTCCCATT GTCCAAAC, r: TGATTGAAGGA-
CAGCTGGAA mouse Hprt f: GCAGTACAGCCCCAAAATGG,
r: AACAAAGTCTGGCCTGTATCCAA; human Hprt f:
Regulation of PTPRJ Expression
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TCAGGCAGTATAATCCAAAGATGGT, r: AGTCTGGCT-
TATATCCAACACTTCG.
Antibodies
Monoclonal hamster anti-mouse CD148 antibody was gener-
ated as described [14] and affinity purified with Protein G
sepharose. This antibody was a gift from Prof. Arthur Weiss
(Howard Hughes Medical Institute, Rosalind Russell Medical
Research Centre for Arthritis, University of California-San
Francisco, San Francisco). Rat anti-mouse Mac-2 monoclonal
antibody (un-purified culture supernatant from clone TIB-166
hybridoma, ATCC) was kindly provided by Dr Andrew Cook,
University of Melbourne. Antibodies to the following proteins
were purchased from commercial sources: F4/80 monoclonal
antibody from Serotec, goat anti-hamster IgG biotin conjugated
(as a secondary against hamster anti-mouse CD148 antibody) from
Pierce and goat anti-rat IgG biotin conjugated (as a secondary
against rat anti-mouse F4/80 and Mac-2 antibodies) from Serotec.
Immunoblotting
Total protein extracts were prepared using the SDS-boiling
method [26]. Cells were washed twice with ice cold PBS and lysed
on the culture plate with 500 mL boiling lysis buffer (66 mM Tris-
HCl pH 7.4, 2% SDS) per 16106 cells. Extracts were homoge-
nised by repeated passage through a 26-gauge needle and further
boiled for 5 minutes. Protein concentration of total lysates was
determined using the BCA assay kit (Pierce, Rockford, IL, USA).
Extracts were resolved by SDS-PAGE (4–12%), transferred to
Imobilon-P (Millipore, North Ryde, NSW, Australia), blocked and
probed with anti-CD148 antibody or antiphosphoprotein anti-
bodies in the presence of phosphatase inhibitors. Blots were
washed, probed with HRP-labelled secondary antibodies (Cell
Signaling Technology) or Streptavidin-HRP-labelled (Pierce)
tertiary antibody in case of CD148 blots, and detected using
enhanced chemiluminescence (ECL) reagents (Amersham Phar-
macia Biotech, Piscataway, NJ, USA). Membranes were stripped
with 66 mM Tris-Cl (pH 6.7)/2% SDS/100 mM 2-mercapto-
ethanol and reprobed with total Akt antibodies (Cell Signaling
Technology).
Immunohistochemistry
Immunohistochemistry was performed using an immunoperox-
idase technique with diaminobenzidine (DAB) as the chromogen
as described previously [21,49]. Expression of CD148, F4/80 and
Mac-2 were examined in serial sections. Briefly, sections were
deparaffinized and rehydrated followed by antigen retrieval. For
CD148, microwave antigen retrieval was performed in citrate
buffer pH 6.0 for 2 min and allowed to cool overnight. For F4/80
Carezyme Trypsin digestion kit (Biocare Medica) was used as per
the manufacturer’s instructions. Sections were washed in Tris
buffered saline (TBS) and endogenous peroxidase activity was
blocked by incubating the sections in 3% H2O2 (diluted in TBS)
for 30 min. Sections were incubated for 60 min in serum block
[10% fetal calf serum (FCS) plus 10% normal serum (species of
secondary antibody) in TBS] and then treated with the primary
antibody for 60 min. Sections were subsequently incubated for
30 min with a biotinylated F(ab9)2 fragment of goat anti-rat or
rabbit anti-hamster immunoglobulin (DakoCytomation), followed
by horseradish peroxidase (HRP)-conjugated streptavidin (Dako-
Cytomation) and developed with DAB chromogen (DakoCytoma-
tion) according to the manufacturer’s specifications. The specificity
of the staining was confirmed by using matched isotype control
antibodies. All sections were counterstained with Mayer’s haema-
toxylin. Slides were allowed to dry on the bench before mounting
using permanent mounting media (Cytoseal, Stephens Scientific).
All incubations were carried out at 25uC sections were washed
between each step with TBS. Slides were examined and
photographed using a transmitted light microscope (Olympus
BX-51, with DP-70 camera).
Statistical Analysis
One-way analysis of variance (ANOVA) was used to determine
any significance differences between the samples. In addition
significance differences between individual time points for each
group were calculated using a two-tailed independent Student’s t-
test. Data sets yielding a p value greater than 0.05 were regarded
as not statistically different.
Results
Ptprj is Preferentially Expressed in Macrophage-enriched
Tissues and Cell Types
To characterize the expression of Ptprj in various mouse tissues,
quantitative real-time PCR analysis was performed. Ptprj expres-
sion was highest in bone marrow derived macrophages (Figure 1A).
Tissue distribution revealed that Ptprj was high in tissues with a
significant macrophage content. In particular, expression of Ptprj
was highest in the spleen. However, other macrophage-rich tissues
such as lung, liver, kidney, intestine, thymus, ovary, muscle and
testis showed detectable expression levels of Ptprj. Minimal
expression of Ptprj was detected in brain, heart and placenta.
The expression of Ptprj in a range of different cell types was also
examined. Ptprj mRNA was expressed at relatively elevated levels
in inflammatory (TEPMs) and primary macrophages (BMMs) and
at lower levels in the macrophage-like cell line RAW 264.7,
differentiated RAW/C4 osteoclast-like cells and myeloid precursor
cell line M1 (Figure 1B). Ptprj mRNA levels were low in pre-B
lymphoid cell line WEHI-231, embryonic fibroblasts and Ptprj
mRNA was virtually undetectable in the fibroblast cell line NIH
3T3.
As Ptprj expression was highest in spleen compared to other
tissues (Figure 1A), immunohistochemistry was performed to
identify the cell types within spleen that express the protein
product of Ptprj, CD148. CD148 expression pattern in the spleen
was restricted to the red pulp region, and was indistinguishable
from the expression pattern of F4/80, a mononuclear phagocyte
marker (Figure 1C). This confirmed the macrophage lineage–
specific expression of CD148 in the mouse spleen and was
consistent with the quantitative real-time PCR data (Figure 1A,B).
Regulation of Ptprj mRNA and Protein in Response to
Inflammatory Stimuli in Mouse Macrophages
Quantitative real-time PCR analysis of BMMs stimulated with
LPS showed regulated expression of Ptprj. In the absence of CSF-1,
LPS induced Ptprj mRNA expression approximately six-fold
peaking at 4 hours. However, the presence of CSF-1 caused a
marked reduction in both the basal and LPS-induced expression
levels of the Ptprj transcript (Figure 2A). As expected, the
expression pattern of c-fms, a classical marker for mature,
differentiated macrophages was suppressed by CSF-1 (Figure 2B).
To investigate other murine macrophage populations, the
expression profile of Ptprj was examined in the macrophage-like
RAW 264.7 cell line and in thioglycollate-elicited peritoneal
macrophages (TEPM). Although, the pattern of Ptprj induction
in response to LPS in RAW 264.7 cells was identical to that of
BMMs (Figure 2C), the fold induction was less compared to
BMMs. Because RAW 264.7 cells are deficient in cell surface
expression of CSF-1R [50], Ptprj mRNA expression in these cells
Regulation of PTPRJ Expression
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was examined only in the absence of CSF-1. As with BMMs, in
TEPM Ptprj was strongly induced by LPS and this was repressed
by CSF-1 (Figure 2D). Pre-treatment of macrophages with IFNc
(priming) results in a more rapid and heightened response to LPS
and other TLR agonists [48,51]. Unlike LPS and CpG DNA,
IFNc alone had no effect on induction of Ptprj in BMMs (data not
shown). Conversely, priming of BMMs with IFNc repressed LPS-
mediated induction of Ptprj mRNA expression at early time points
(Figure 3E).
To determine whether Ptprj was regulated at the protein level,
western blot analyses of BMM cell lysates from LPS and CpG time
courses were performed (Figure 2F). CSF-1 increased the basal
level of CD148 protein (0 h lanes), however CD148 protein levels
increased with time after treatment with LPS in both replete and
CSF-1-starved cells. Although CpG DNA showed a similar basal
Figure 1. Ptprj mRNA expression in murine tissues. (A). qPCR of Ptprj from RNA extracted from mouse tissues. (B) qPCR of Ptprj from RNA from
pre-B lymphoid cell line WEHI-231, osteoclast-like cell line (RAW 264.7, C4), TEPM, macrophage-like cell line (RAW 264.7), BMM, myeloid cell line M1
and fibroblasts (NIH3T3 and mouse embryonic). (C). Immunohistochemistry of cell-specific expression of PTPRJ in mouse spleen sections. Sections
were immunostained for CD148 (A1, B1) or F4/80 (A2, B2) and with CD148 (C1) and F4/80 (C2) isotype control antibodies. All sections were
counterstained with haematoxylin. RP, red pulp; WP, white pulp. Original magnification: x100 (A), x200 (B, C). Bar, 100mm.
doi:10.1371/journal.pone.0068306.g001
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pattern of induction of CD148 by CSF-1, an increased level of
CD148 protein with time after stimulation was observed. Thus
both qPCR (Figure 2D) and western blotting (Figure 2F) showed
an increase in CD148 mRNA and protein respectively, albeit with
a different timecourse.
Regulation of PTPRJ Gene Expression in Human
Mononuclear Phagocytic Cells
The expression profile of PTPRJ in response to LPS was also
examined in the human monocytic cell line THP-1 and in human
dendritic cells. Unlike mature differentiated macrophages such as
RAW 264.7 cells or BMMs, THP-1 cells are premonocytes that
are committed to the monocytic lineage, but are non-adherent and
lack many macrophage-specific cell surface markers. Therefore,
for the induction of terminal differentiation to macrophage-like
cells, THP-1 cells were cultured in the presence of PMA. PMA
mimics some actions of CSF-1, but activates distinct signalling
pathways [52]. In the absence of PMA, LPS stimulation had no
effect on PTPRJ expression (Figure 3A). However, presence of
PMA led to a dramatic induction of PTPRJ in response to LPS.
Even in the absence of LPS, PMA induced basal PTPRJ
expression approximately ten-fold, whereas in the presence of
LPS, the induction was even stronger. PMA strongly induced c-
fms, consistent with the view that PMA imparts a macrophage-like
phenotype to these monocytic cells, however LPS treatment
suppressed c-fms expression in PMA-differentiated cells
(Figure 3B).
CD148 has been recognised as an accessory molecule present
on the surface of peripheral blood dendritic cells [53]. Although
overall fold induction was lower than in mouse macrophages, LPS
induced PTPRJ expression in human peripheral blood dendritic
cells (PBDCs) (Figure 3C). As with PMA-differentiated THP_ cells,
Figure 2. Regulation of Ptprj expression in mouse macrophages by proinflammatory stimuli. A–C: Regulation of Ptprj expression by CSF-1
and LPS in mouse bone marrow-derived macrophages (BMMs). BMMs were maintained overnight in the presence or absence of CSF-1 (16104 U/mL)
before treatment with LPS (10 ng/mL) (A, B). RAW 264.7 cells were maintained overnight in the absence of CSF-1 before treatment with LPS (10 ng/
mL) (C). Ptprj (A, C) and c-fms (B) expression profiles were assessed by quantitative real-time PCR. Profiles are representative of two independent
experiments. D: Regulation of Ptprj expression by CSF-1 and LPS in mouse thioglycollate-elicited peritoneal macrophages (TEPMs). TEPMs were
maintained overnight in the presence or absence of CSF-1 (16104 U/mL) before treatment with LPS (10 ng/mL). Ptprj expression profile was assessed
by quantitative real-time PCR. E: IFNc treatment of bone marrow derived macrophages suppresses the LPS mediated induction of ptprj. BMMs were
maintained overnight in the presence of CSF-1 (16104 U/mL) and presence or absence of IFNc (500 pg/mL) before treatment with LPS (10 ng/mL).
RNA was extracted at each time point and used for the synthesis of cDNA. Ptprj expression profile was assessed by quantitative real-time PCR.
Datapoints (+/2 SD) represent the average of triplicate samples each from triplicate independent experiments. Significance values were determined
by one-way analysis of variance (ANOVA). *denotes p,0.05; **denotes p,0.005; n = 3. F: Regulation of PTPRJ protein in response to LPS, CpG DNA
and CSF-1. BMMs were maintained overnight in the presence or absence of CSF-1 (16104 U/mL) before treatment with LPS (10 ng/mL) [top panel] or
CpG DNA (0.1 mM) [bottom panel]. Protein lysates were separated by SDS-PAGE, transferred to PVDF membranes and immunoblotted for PTPRJ. The
membrane was then stripped, and reprobed for total Akt as a loading control. Profiles are representative of two independent experiments.
doi:10.1371/journal.pone.0068306.g002
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c-fms was down-regulated by LPS in human dendritic cells
(Figure 3D).
Expression of Long Noncoding RNA Ptprj-as1 during
Macrophage Activation
Expression of Ptprj-as1 in murine tissues. In a previous
study, we examined microarray expression profiling data of
mammary epithelial cells derived from pregnant, lactating and
involuting mice [34]. The microarray that this dataset is based
upon features probes targeting ,29,550 mRNAs and 8,693 long
ncRNAs. Within this dataset, we identified seven probes that
targeted long ncRNAs that originated from the Ptprj locus [21]. All
of these long ncRNAs occurred within the first intron of Ptprj; two
were on the antisense strand and the remaining five were on the
sense strand (Figure 4A). On the basis of its high expression in
monocytic cells, cytoplasmic localization, and spliced character,
we selected the lncRNA that we term Ptprj-as1 (GenBank
Accession ID AK016880) for further examination. As the other
lncRNAs were expressed at low levels or unexpressed in monocytic
cells, and they were derived from unspliced transcripts, they were
not pursued for further characterization as such low-expressed
single-exon transcripts are challenging to study because they
cannot be easily distinguished from genomic DNA in expression
studies.
Ptprj-as1 is a spliced 1,006 nt lncRNA that is transcribed
antisense to Ptprj-as1 and is expressed at levels similar to Ptprj.
Figure 3. Ptprj expression in response to LPS in human mononuclear phagocytic cells. THP-1 cells were maintained for 24 hours in the
presence or absence of PMA (1027 M) to induce differentiation, before treatment with LPS (10 ng/mL) (A, B). Human dendritic cells were treated with
LPS (10 ng/mL) over a time course (C, D). Ptprj (A, C) and c-fms (B, D) expression profiles were assessed by quantitative real-time PCR. Datapoints (+/2
SD) represent the average of triplicate samples. Significance values were determined by one-way analysis of variance (ANOVA). *denotes p,0.05;
**denotes p,0.005; n = 3. *denotes p,0.05; **denotes p,0.005; n = 3.
doi:10.1371/journal.pone.0068306.g003
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Interestingly, Ptprj-as1 is antisense to the 59UTR of a short isoform
of Ptprj that lacks the canonical first exon, raising the possibility
that Ptprj-as1 may be co-expressed with the short isoform of Ptprj-
as1. Ptprj-as1 was identified as a long noncoding RNA of unknown
function that is transcribed from the reverse strand of the Ptprj
gene (Figure 4A). Note that the PTPRJ-AS1 in human is in a
different location to Ptprj-as1 in mouse and should not be
considered as an orthologue (Figure 4B). RT-PCR analysis of
the murine transcript in different tissues confirmed the existence of
tissue-specific splice variants (Figure 4C). Spleen, brain, and testis
revealed two isoforms of Ptprjas-1, one; as reported previously [21]
and a second that contains an additional 80 base exon (Figure 4D).
The examination of the secondary structure of the additional exon
showed a stable stem loop structure (Figure 4E).
Expression of Ptprj-as1 in murine macrophages. Ptprj-as1
was readily detectable by qRT-PCR (Figure 5A). Preliminary
screens of murine tissues demonstrated that whilst Ptprj-as1 was
expressed in many tissues, the transcript showed comparatively
elevated levels in lung, brain, kidney and spleen; all tissues that
have a sizeable macrophage component (Figure 5A). In unstimu-
lated cells, LPS activation of murine bone marrow-derived
macrophages (BMMs) induced a transient increase of Ptprj mRNA,
peaking at a 4 fold increase 8 hours post addition of LPS. In
parallel with Ptprj, Ptprj-as1 expression was also transiently induced
by LPS activation of BMMs (Figure 5B). Furthermore, Pam3Cys
induced a very similar expression pattern of Ptprj and Ptprj-as1
(Figure 5C). The comparable expression trends of Ptprj and Ptprj-
as1 during mBMM activation is consistent with the developing
hypothesis that the Ptprj and Ptprj-as1 are regulated by the activity
of the same promoter.
Bioinformatic Identification of Regulatory Sequences in
the Ptprj Gene
To further investigate the potential mechanisms that direct the
expression of Ptprj, bioinformatic analysis to identify putative
promoter regions was performed.
Identification of Ptprj putative promoter by CAGE
analysis. CAGE (cap analysis of gene expression) analysis
identified the dominant start sites for transcription of the mouse
and human Ptprj genes, which in turn allowed functional
alignment of the promoters. Ptprj appears to have only one
promoter, and both the mouse and human Ptprj promoters lack a
TATA box and are rich in GC (data not shown). Whilst the
majority of the macrophage-specific promoters also lack a TATA
box [54–56] the Ptprj promoter differs from typical macrophage
promoters such as c-fms [57,58] in that these generally lack GC-
rich elements. Analysis of the Ptprj-as1 promoter did not reveal the
presence of either a TATA-box or GC-rich element, suggesting
that it may be regulated independently to Ptprj.
Identification of Putative Transcription Factor Binding
Sites
The mouse and human sequences corresponding to ECR1 were
aligned using ClustalW alignment. This sequence was further
examined for consensus transcription factor binding sites con-
served in sequence and position between mice and humans using
the RVista browser and TRANSFAC (Figure 6). This analysis
revealed the presence of multiple transcription factor binding sites
that are conserved in both sequence and position between the
mouse and human putative promoters. These include many
transcription factor binding sites that are commonly functional in
myeloid promoters including PU.1, SP1, myeloid zinc finger
protein (MZF1), nuclear factor kappa B (NF-kB) or p50, octamer
factor binding sequences (OCT) and acute myelogenous leukemia
(AML1). The presence of a CpG island upstream of the
transcription start site might permit epigenetic control of
transcriptional activity of the Ptprj promoter [58,59]. One
important observation of the assignment of TSS by CAGE is that
the Ptprj mRNA is longer than previously appreciated. As a
consequence, there may be up to four potential initiation codons
or AUGs (uAUGs) in the 59 untranslated region (UTR) upstream
of the putative start site of translation of CD148.
Discussion
PTPRJ has been widely accepted as an epithelial cell expressed
gene and has been proposed to be a tumor suppressor in this cell
type. However, we show here that Ptprj is highly expressed in
macrophages and its expression is regulated in response to CSF-1
and proinflammatory stimuli. Ptprj expression was highest in
spleen, lung, ovary, liver, kidney, intestine, thymus and testis;
tissues that are rich in resident macrophage population. Indeed,
approximately 18% of the cells in the spleen (the highest
expressing tissue for Ptprj) are macrophages [60]. Others have
shown CD148 is expressed in macrophages and related tissues of
human origin [61]. The macrophage-enriched expression of
CD148 was further confirmed by the strong correlation of the
expression pattern of CD148 and F4/80 surface markers on the
splenic macrophages in the red pulp. qRT_PCR showed a
transient increase in CD148 mRNA after stimulation with
proinflammatory factors such as LPS, and that both basal and
stimulated expression is suppressed by CSF-1. Western blotting
showed a general sustained increase in CD148 protein after LPS
stimulation but no detectable suppression by CSF-1. Although the
reason for this discrepancy is unknown, lack of correlation
between RNA and protein may be related to the half-life of the
protein within the cell. For example, if CD148 has a long half-life
(as many membrane/cytoskeletal proteins do), then a short-term
down-regulation in mRNA levels would not immediately translate
into a down-regulation of protein. On the contrary, protein with a
long half-life would continue to appear up-regulated due to the
accumulation of the protein in the cell before degradation.
Whilst there have been a number of studies investigating the
role of Ptprj in both epithelial and haematopoietic cells, its exact
role in cell function has not been defined. Overall, Ptprj appears to
be a negative regulator of cell proliferation in epithelial cells and
fibroblasts, by down-regulating receptor tyrosine kinase activity
[16,17,20]. In contrast, Ptprj plays a positive role in the activation
of B cells and monocytes by dephosphorylating the negative
regulatory carboxyterminal tyrosine of src family kinases (SFK),
thereby activating these enzymes and potentiating a signalling
cascade. Ptprj expression has been reported to be up-regulated in
epithelial cells as they reach confluence and is down-regulated in
some tumours [16,17]. Although loss of heterogeity has been
reported for colon, lung, breast and thyroid cancers [62], we have
Figure 4. Characterisation of Ptprj-as1. A–B: Ptprj-as1 maps to the reverse strand within the boundaries of the murine Ptprj gene. Comparison of
the mouse Ptprj (A) and human PTPRJ (B) loci. Protein coding transcript isoforms of Ptprj/PTPRJ are shown in red and long noncoding transcripts are
shown in blue. Arrows indicate the direction of transcription. The human microRNA miR-3161 is shown in green. Position of PCR primers used for
qRT-PCR for mouse Ptprj-as1 are indicated. C-D: Mapping (C) and expression (D) of a splice variant of murine Ptprj-as1 in brain, kidney and testis. E:
Predicted secondary structure of Ptprj-as1 splice variant.
doi:10.1371/journal.pone.0068306.g004
Regulation of PTPRJ Expression
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e68306
not detected any major down-regulation of PTPRJ protein or
mRNA in a large cohort of breast cancers [21].
Clearly, the regulation of Ptprj is of profound importance in a
number of cell types, however the regulation of PTPs in general
and Ptprj in particular is poorly understood [11]. Ptprj translation
has been shown to be regulated by the use of an alternative start
site at the 59 end of the gene [33]. There is growing evidence that
microRNAs (miRNAs) can target the expression of both
oncogenes and tumour suppressor genes and recently miRNA-
328 has been reported to decrease Ptprj expression in epithelial
cells [46]. In contrast to the relatively few miRNAs that have been
identified, it appears that there are at least as many long
noncoding RNAs (lncRNAs) as coding RNAs in the human
genome [45,63], and it is likely that many of these can regulate
gene expression [64]. We have identified a lncRNA, Ptprj-as1, that
is transcribed off the Ptprj gene locus and is co-regulated with Ptprj
coding transcripts in murine monocytes. Although we have not
investigated any direct roles of Ptprj-as1 in regulating Ptprj, its
tissue-specific expression and co-incident location with Ptrpj in the
genome, raise the possibility that it may have some role in the
expression or splicing of Ptprj. Previous studies have revealed that
antisense long ncRNAs can directly affect the expression or
alternate splicing of nearby genes. For example, expression of a
long ncRNAs antisense to the tumor-suppressor gene p15 results in
silencing of the p15 gene by inducing heterochromatin formation
[65]. In another example, differential expression of the lncRNA
LUST, which originates antisense to an intronic region of RBM5,
regulates the expression of RBM5 splice variants [66]. It also
noteworthy that Ptpre, a related tyrosine phosphatase-encoding
gene, also features a contextually analogous antisense noncoding
RNA, Ptpreas [67]. Finally, although examination of the corre-
sponding Ptprj loci in the human genome revealed a number of
Figure 5. Expression of Ptprj-as1 in murine tissues and in response to TRL ligands. A: Expression of Ptprj-as1 in murine tissues. B, C: Ptprj
and Ptprj-as1 mRNA expression in BMMs in response to LPS (B) or Pam3Cys (C). mRNA expression was quantified by qRT-PCR and expressed as fold
change compared with untreated (0h). Plots represent mean fold change +/2 SD; n = 3. Significance values were determined by one-way analysis of
variance (ANOVA). *denotes p,0.05; **denotes p,0.005; n = 3. *denotes p,0.05; **denotes p,0.005; n = 3.
doi:10.1371/journal.pone.0068306.g005
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lncRNAs, because the human PTPRJ loci differs considerably in
terms of both splice variants, exon number, primary sequence, and
promoter initiation, it is not possible to identify orthologous
lncRNAs. This in itself is not surprising, as lncRNAs seldom reveal
identifiable primary sequence conservation, and as an intrinsic
feature of their regulatory function as RNAs are thought generally
to show great plasticity in their sequence constraints compared to
protein-coding genes [37].
CAGE analyses revealed the presence of clustered transcription
start sites in both mouse and human Ptprj promoters, including
conserved multiple upstream AUG (uAUG) codons in the 59 UTR
(data not shown). These uAUGs are common features of mRNAs
that encode regulatory proteins. These upstream open reading
frames (uORFs) encode for upstream peptides (uPEPs), which are
highly evolutionarily conserved and are important for regulating
translation of the main CDS [68,69]. It is conceivable that one of
Figure 6. Clustal W alignment of the mouse and human Ptprj putative promoters. Consensus transcription factor binding sites conserved in
sequence and position between mouse and human were predicted using RVista browser and TRANSFAC. Only the myeloid-specific transcription
factors have been shown in this figure. Evolutionary conserved region (ECR1) lies within the blue brackets. Blue line marks the region of transcription
start site (TSS) cluster represented in Figure 6. mTSS refers to the transcription start site for mouse ptprj and hTSS to the transcription start site for
human Ptprj predicted by CAGE analysis. The four uAUG codons are highlighted within grey boxes and the stop codons within red boxes. Asterisk (*)
represents the translation start site. The boxes represent the conserved sequences between mouse and human. N represents any nucleotide.
doi:10.1371/journal.pone.0068306.g006
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these AUGs is the preferred start codon, instead of the one
(marked with asterisk in Figure 6) recognised by the publicly
available sequence databases. As shown in Figure 6, there is a
conserved stop codon in the 59 UTR and another in the mouse
putative promoter. In addition, translational analysis initiating
from the fourth uAUG encodes for a 52 amino acid long peptide
in case of mouse Ptprj.
As there was a similar pattern of Ptprj gene regulation across a
range of mouse and human macrophages, a combination of
bioinformatic data mining and functional analysis was used to
dissect the potential mechanisms underlying the transcriptional
regulation of Ptprj. NF-kB binding sites were identified in the Ptprj
promoter (Figure 6). NF-kB has a key role in inflammation as it
regulates apoptosis, cell-cycle progression, proliferation and cell
differentiation [70,71]. The responsiveness of both mouse and
human Ptprj genes to LPS and CpG DNA could therefore be
attributed to the presence of an NF-kB binding site in the Ptprj
putative promoter.
The Ptprj promoter is a GC-rich TATA-less promoter, which is
the major promoter class in mammals and is a more broad and
evolvable category of promoters compared to the TATA box-
containing promoters [59]. A number of multiple transcription
factor binding sites that are conserved in both sequence and
position between the mouse and human putative promoters were
identified. The presence of PU.1, SP1, MZF1, NF-kB, AML1 and
OCT binding sites in the Ptprj promoter could explain the
macrophage-specific expression of Ptprj. Many myeloid promoters
have a functional PU.1 binding site upstream of the transcription
start site. PU.1 binds to and recruits TATA binding protein (TBP),
the primary component of the basal transcription factor TFIID in
promoters lacking a TATA box [55,72]. The expression of PU.1
has been shown to be important for macrophage differentiation
and the expression of a number of molecules that mediate some of
the immunological actions of macrophages [73]. Amongst other
transcription factors that are involved in myeloid gene regulation
and can interact with TBP are SP1 and OCT [55]. MZF1
expression is restricted to myeloid cell lines and is implicated in the
development of cells of the myeloid lineage. The presence of a
conserved MZF1 binding site in the Ptprj promoter is consistent
with its expression in myeloid cells. The RNA binding zinc finger
proteins EWS and FUS/TLS bind to the consensus binding sites
for MZF1, implicating their significance in the assembly of the
basal transcriptional complex [74]. Taken together, the bioinfor-
matic analyses of the Ptprj putative promoter revealed that the Ptprj
gene is highly regulated in macrophages and the Ptprj promoter
resembles a macrophage-specific promoter.
IFNc augments the immune response to LPS and other TLR
agonists, thereby orchestrating distinct cellular signalling pathways
through transcriptional control over a large number of genes [50].
In contrast, IFNc priming of BMMs repressed Ptprj induction in
response to LPS at early time points and had no effect at later time
points (Figure 2E). Thus, Ptprj differs from many other macro-
phage-specific genes, which are regulated by both LPS and IFNc.
Many LPS-inducible genes including Mpeg-1, Itm2b and Ramp2,
are repressed by CSF-1, but LPS-inducible in the presence of
CSF-1 [75]. However, LPS-induction of Ptprj expression was more
pronounced in the absence of CSF-1. In this respect, Ptprj
regulation is similar to that of Tlr9, as absence of CSF-1 causes an
elevation in Tlr9 mRNA expression, but differs in response to
IFNc. In both mouse macrophages and human monocytes or
dendritic cells, LPS induced CD148 expression whereas it
repressed c-fms expression. Thus the increases in Ptprj gene
expression are unlikely to be dependent on CSF-1 signalling, as
LPS treatment not only suppresses expression of the CSF-1
receptor (C-fms) but also induces cleavage of the surface receptor
making cells refractive to CSF-1 [75]. Dendritic cells are a
heterogeneous population of cells with a number of different
lineage relationships. C-fms is downregulated upon differentiation
of monocytes into myeloid-derived dendritic cells and is also
expressed at lower levels in other debdritic cell polulations [76].
Whilst expression is low in these cells, clearly, c-fms is functional
since absence of CSF-1 results in .50% reduction in dendritic cell
numbers [76], and CSF-1 can also regulate the number of tissue
and blood elicited dendritic cells [77–79]. Thus ligation of CSF-1
to its receptor c-fms, provides both survival and differentiation
signals for dendritic cells [80].
CD148 expression is up-regulated in chronic inflammatory
diseases, such as Crohn’s disease and Cogan’s syndrome [61,81].
The possible function of CD148 in inflammation could be similar
to that of CD45, which plays an important role in lymphocyte
development and function and has a crucial role in inflammation
and cancer [82]. CD45 enhances T-cell and BCR signalling by
dephosphorylating the auto-inhibitory phospho-tyrosine residues
on Src family tyrosine kinases (SFKs) [83]. Indeed, recent studies
of double knockout mice have revealed that CD45 and CD148
have overlapping functions, and can activate src family kinases in
monocytes [84]; therefore activation or enhancement of CD148
expression could lead to modulation of the inflammatory response.
The current results indicate that Ptprj is highly regulated by
inflammatory stimuli in vitro and in vivo, however, the precise
mechanism involved in the regulation of inflammation by Ptprj
remains to be elucidated.
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